The Alabama Department of Public Health (ADPH) is investigating reports of adverse reactions to the antibiotic ceftriaxone, commonly known as Rocephin. As of Tuesday, Jan. 21, the ADPH has received 11 reports of reactions occurring within the last few months in Alabama.
The ADPH has not disclosed the identities of the affected individuals or the clinics where the injections took place. According to the agency, some cases exhibited symptoms consistent with anaphylactic reactions, including hives, itching, low blood pressure, and difficulty breathing. These symptoms were successfully treated using standard measures for anaphylaxis.
“Persons investigated have had a variety of comorbid conditions, and no specific causal link between ceftriaxone and these reactions has been identified at this time,” ADPH stated. Comorbidities refer to medical conditions such as diabetes or hypertension that exist alongside a primary diagnosis.
The ADPH emphasized that allergic reactions to injectable antibiotics, including ceftriaxone, are not uncommon. Reactions occur in 0.5% to 2.5% of patients using cephalosporins like Rocephin. The agency urged healthcare providers to remain vigilant when administering these medications and to monitor patients for potential allergic responses.
In Mississippi, the State Department of Health is aware of the situation and is closely monitoring developments. Some clinics in north Mississippi, including RedMed clinics in Pontotoc and New Albany, have suspended the use of Rocephin as a precautionary measure.
The investigation into these adverse reactions is ongoing. For now, the ADPH reminds healthcare providers and patients to be cautious and prepared when using injectable antibiotics.
